
This medtech startup got acquired by Medtronic (here’s how you can do it)
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
By:
About this listen
I'm joined by Brian More, CEO at Nanovis, a nanotechnology company that's transforming patient outcomes through breakthrough surface engineering innovations.
In this episode, we jump into:
The Nanotechnology Impact in Spinal Implants
→ Nanovis creates surfaces that mimic natural bone structure at the nanoscale, dramatically improving osseointegration rates
→ Their proprietary nanotopography increases surface area by 30-40x compared to traditional smooth implants, accelerating bone growth
→ The technology reduces healing time from months to weeks by creating optimal conditions for osteoblast attachment and proliferation
From Academia to Commercial Success: The Nanovis Journey
→ How demonstrating clear clinical superiority over existing titanium coating technologies landed them funding
→ How strategic partnerships with major implant manufacturers accelerated market penetration without requiring massive sales infrastructure
Breaking Through FDA Regulatory Barriers
→ Why positioning their technology as a surface modification rather than a new device class helped secure FDA clearance
→ Demonstrating substantial equivalence while still showing enhanced performance through the 510k pathway
→ Why they showed clinical data and compared to the industry standard (and why it actually mattered)
Future of Nanotechnology in Medical Devices
→ Surface engineering will become standard across all implantable devices, not just spinal hardware
→ Next-generation developments include drug-eluting nanosurfaces that release therapeutic compounds over time
→ AI-driven surface optimization will create patient-specific nanotopographies based on individual bone density and healing patterns
Building Strategic Partnerships in Medtech
→ Success required finding partners who understood the long-term value proposition despite higher upfront development costs
→ International expansion focused on markets with faster regulatory pathways to prove clinical efficacy before US scaling
→ Licensing agreements include milestone-based payments tied to clinical outcomes rather than just unit sales
Best Quotes:
"We're not just making implants rougher - we're engineering surfaces at the molecular level to speak the same language as human bone cells."
"The biggest mistake in medtech is thinking that better technology automatically wins. You need better outcomes, and you need to prove them."
"Nanotechnology isn't the future of medical devices - it's happening right now. The question is whether you're going to be part of it or get left behind."
"Surgeons don't care about your surface area calculations. They care about whether their patients are walking pain-free six months later."
Want more insights on medtech innovation? Subscribe to the channel so you don't miss hot takes and insider tactics from the trenches of medtech startups.
🤝 Join the #1 network for medtech innovators on the internet. Become a member to accelerate your journey, collaborate and build valuable ventures. Join for free using this link - https://xo-medtech.circle.so/join?invitation_token=3be7a91cf85779cc999d33b732b75eb3b2a28aec-df0574a8-8af4-45b4-9013-d40d0596a899
Find the perfect vendors for your medtech project for free at MedtechVendors - https://www.medtechvendors.com/
📈 My FREE 5-day course for Medtech Innovators to create successful ventures: https://xomedtech.com/free-course
FIND SPENCER JONES ON SOCIAL
Spencer's LinkedIn - https://www.linkedin.com/in/medtech-innovation/
XO Medtech LinkedIn - https://www.linkedin.com/company/xo-medtech
FIND BRIAN MOORE ON SOCIAL
Brian's LinkedIn Profile - https://www.linkedin.com/in/brian-more-75526812/
Nanovis Website - https://nanovistechnology.com/
Episode Timestamps:
0:00 - Introduction to Brian Moore and Nanovis nanotechnology breakthrough
3:15 - The science behind nanosurface engineering for bone integration
8:42 - Brian's transition from spine surgeon to medtech CEO
12:30 - Early funding challenges and investor education on nanotechnology
16:45 - FDA regulatory pathway strategy for surface modification technology
21:20 - Manufacturing scalability challenges in nanotechnology production
26:10 - Clinical trial results and surgeon adoption strategies
31:55 - Partnership approach vs. direct competition with major implant companies
37:40 - International expansion and market penetration tactics
42:25 - Future applications of nanotechnology across medical devices
47:15 - Drug-eluting surfaces and next-generation product development
52:30 - AI integration for personalized nanosurface optimization
56:45 - Key advice for medtech entrepreneurs entering competitive markets